Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Dec 21;62(1):e01396-17.
doi: 10.1128/AAC.01396-17. Print 2018 Jan.

A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates

Dylan Jones  1 , Ramy H Elshaboury  2 , Erik Munson  3 , Thomas J Dilworth  4
Affiliations
Comparative Study

A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates

Dylan Jones et al. Antimicrob Agents Chemother. .

Abstract

mecA-positive Staphylococcus aureus isolates phenotypically susceptible to cefoxitin (mecA-methicillin-sensitive S. aureus [MSSA]) have been identified. We describe the treatment and outcomes among patients with mecA-MSSA bloodstream infections (BSI) and MRSA BSI matched 1:1 for age, BSI origin, and BSI type (n = 17 per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%, P = 0.010), driven largely by persistent bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for poor clinical outcomes.

Keywords: bacteremia; mecA PCR; mecA-positive methicillin-susceptible S. aureus; methicillin-resistant S. aureus; vancomycin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Proulx MK, Megan K, Gandra S, Torres B, Weir S, Stiles T, Ellison RT III, Goguen JD. 2016. Reversion from methicillin susceptibility to methicillin resistance in Staphylococcus aureus during treatment of bacteremia. J Infect Dis 213:1041–1048. doi:10.1093/infdis/jiv512. - DOI - PMC - PubMed
    1. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. 2012. Predictors of mortality in Staphylococcus aureus Bacteremia. J Clin Microbiol Rev 25:362–386. doi:10.1128/CMR.05022-11. - DOI - PMC - PubMed
    1. CLSI. 2017. Performance standards for antimicrobial susceptibility testing; approved standard, 27th ed CLSI document M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Munson E, Kramme T, Culver A, Hryciuk JE, Schell RF. 2010. Cost-effective modification of a commercial PCR assay for detection of methicillin-resistant or -susceptible Staphylococcus aureus in positive blood cultures. J Clin Microbiol 48:1408–1412. doi:10.1128/JCM.02463-09. - DOI - PMC - PubMed
    1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55. doi:10.1093/cid/ciq146. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources